<DOC>
	<DOCNO>NCT00306163</DOCNO>
	<brief_summary>The aim study compare responsiveness low airway adult patient stable asthma treatment ciclesonide fluticasone propionate . Treatment medication administer follow : ciclesonide inhale daily one dose level , fluticasone propionate inhale twice daily one dose level . The study duration consist baseline period ( 5 week ) treatment period ( 5 week ) . The study provide data safety tolerability ciclesonide .</brief_summary>
	<brief_title>Responsiveness Lower Airways Adult Patients ( 18-60 Years ) With Stable Asthma After Treatment With Ciclesonide Fluticasone Propionate ( BY9010/NL-101 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Main History bronchial asthma FEV1 &gt; 1.20 L Positive Skin Prick Test Not 500 mcg/day fluticasone propionate equivalent least 28 day prior baseline visit Main Clinically relevant abnormal laboratory value Concomitant severe disease , disease expect interfere outcome study disease contraindication use inhaled steroid Chronic obstructive pulmonary disease ( COPD ) /or relevant lung diseases One asthma exacerbation within 2 month 3 exacerbation within last year prior baseline visit Current smokers exsmokers 10 pack year , smoke within 1 year prior baseline visit Positive response saline challenge baseline visit Positive bronchial hyperresponsiveness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>AMP</keyword>
	<keyword>Ciclesonide</keyword>
	<keyword>Fluticasone propionate</keyword>
</DOC>